Axatilimab-csfr
Brand names: Niktimvo · Active ingredient: Axatilimab
In short: NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
What is Axatilimab-csfr used for?
NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Axatilimab-csfr dosage
For patients weighing at least 40 kg, administer NIKTIMVO 0.3 mg/kg, up to a maximum dose of 35 mg, as an intravenous infusion over 30 minutes every 2 weeks until progression or unacceptable toxicity.
Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), creatine phosphokinase (CPK), amylase, and lipase prior to the start of NIKTIMVO therapy, every 2 weeks for the first month, and every 1 to 2 months thereafter until abnormalities are resolved.
For recommended NIKTIMVO dosage modifications due to adverse reactions, see Table 1.
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; ALP = alkaline phosphatase; CPK = creatine phosphokinase.
Adverse Reaction | SeverityGraded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5. | Dosage Modification
Infusion-related reactions | Grade 1 or 2 | Temporarily interrupt the infusion until resolution or decrease infusion rate by 50%.
Initiate symptomatic treatment (e.g., antihistamines and antipyretics).
For subsequent infusions, premedicate and resume the infusion at 50% of the prior infusion rate.
Grade 3 or 4 | Permanently discontinue NIKTIMVO.
Elevation of AST or ALT (on the day of dosing) | Grade 3 with total bilirubin ≤ Grade 1 | Withhold NIKTIMVO until recovery to Grade 2, then resume NIKTIMVO at 0.2 mg/kg (maximum 23 mg) every 2 weeks.
Elevation of AST or ALT (regardless of the time of the reaction) | ALT or AST ≥ 3 times ULN with total bilirubin ≥ 2 times ULN and ALP < 2 times ULN | Withhold NIKTIMVO and investigate for drug-induced liver injury. If confirmed, permanently discontinue NIKTIMVO.
Grade 4 | Permanently discontinue NIKTIMVO.
Elevation of CPK, amylase, or lipase | ≥ Grade 3 | If diagnostic evaluation results show no evidence of end-organ damage, continue NIKTIMVO without dose reduction.
If diagnostic evaluation results show evidence of end-organ damage, permanently discontinue NIKTIMVO.
Symptomatic ≥ Grade 3 | Permanently discontinue NIKTIMVO.
Other Nonhematologic Adverse Reactions | Grade 3 | Withhold NIKTIMVO until recovery to Grade 2:
If delayed by ≤ 4 weeks from the planned infusion, resume NIKTIMVO at 0.2 mg/kg (maximum 23 mg) every 2 weeks.
If delayed by > 4 weeks from the planned infusion, permanently discontinue NIKTIMVO.
Grade 4 | Permanently discontinue NIKTIMVO.
NIKTIMVO 9 mg and 22 mg are available in different concentrations:
9 mg/0.18 mL
9 mg/0.9 mL
22 mg/0.44 mL
22 mg/2.2 mL (10 mg/mL)
Prior to preparation, check the vial labels to confirm which concentration is being used to avoid dosing errors, including underdosage and overdosage .
Preparation
Use aseptic technique to prepare NIKTIMVO. …
How to take Axatilimab-csfr — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Infusion-Related Reactions
Advise patients and caregivers that reactions related to the infusion may occur during NIKTIMVO treatment. Inform patients and caregivers of the signs and symptoms of infusion-related reactions and to seek medical care should signs and symptoms occur .
Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with NIKTIMVO and for 30 days after the last dose .
Lactation
Advise women not to breastfeed during treatment and for 30 days after the last dose of NIKTIMVO .
Manufactured by:
Incyte Corporation
Wilmington, DE 19803
U.S. License No.2228
Licensed from:
Syndax Pharmaceuticals, Inc.
New York, NY10017
NIKTIMVO and the NIKTIMVO logo are trademarks of Incyte.
Patent Information: www.incyte.com/patents
© 2026 Incyte Corporation. All rights reserved.
Warnings & precautions
Do not take this medicine if: None.
NIKTIMVO can cause infusion-related reactions. Infusion-related reactions, including hypersensitivity reactions, occurred in 18% of patients who received NIKTIMVO in the clinical trial (AGAVE-201), with Grade 3 or 4 reactions in 1.3% .
Premedicate with an antihistamine and an antipyretic for patients who have previously experienced an infusion-related reaction to NIKTIMVO . Monitor patients for signs and symptoms of infusion-related reactions, including fever, chills, rash, flushing, dyspnea, and hypertension. Interrupt or slow the rate of infusion or permanently discontinue NIKTIMVO based on severity of the reaction .
Based on its mechanism of action, NIKTIMVO may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with NIKTIMVO and for 30 days after the last dose .
Axatilimab-csfr side effects
The following adverse reactions are described elsewhere in the labeling.
Infusion-Related Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Chronic Graft-Versus-Host Disease
The safety of NIKTIMVO was evaluated in 79 adult and pediatric patients with cGVHD treated with NIKTIMVO 0.3 mg/kg intravenously every 2 weeks in the AGAVE‑201 trial . The median duration of treatment was 10.3 months (range: 0.5 to 28.6 months), and 73.4% were treated for more than 6 months.
Serious adverse reactions occurred in 44% of patients who received NIKTIMVO. Serious adverse reactions in more than 2 patients included infection (pathogen unspecified), viral infection, and respiratory failure. Permanent discontinuation of NIKTIMVO due to an adverse reaction occurred in 10% of patients and dose reduction due to adverse reaction occurred in 8% of patients. Dose interruptions due to an adverse reaction occurred in 44% of patients. The adverse reactions leading to dose interruption in more than 2 patients were viral infection, infection (pathogen unspecified), bacterial infection, musculoskeletal pain, and pyrexia. …
About this medicine
Axatilimab-csfr is a CSF-1R–blocking antibody. Axatilimab-csfr is a humanized IgG4 (kappa light chain) monoclonal antibody produced in Chinese hamster ovary cells. Axatilimab-csfr has an approximate molecular weight of 150 kDa.
NIKTIMVO (axatilimab-csfr) injection is a sterile, preservative-free, slightly opalescent, pale brownish yellow solution for intravenous use. The solution is free from visible particles.
Each single-dose vial contains 9 mg or 22 mg of axatilimab-csfr at a concentration of 10 mg/mL or 50 mg/mL. Each mL of solution contains citric acid monohydrate (3.6 mg), glycine (9.38 mg), polysorbate 80 (0.5 mg), sodium citrate (8.49 mg), sucrose (42.79 mg) and Water for Injection, USP. The pH is 5.0.
How it works: Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID bb6dba23-e7a6-4765-a1e6-b9e277ce0381. Read the full official label on DailyMed.